Amgen stock edges higher as KRAS lung cancer data and revenue growth support outlook

Amgen Inc. (ISIN US0311621009) reported higher revenue in 2024 while advancing its oncology portfolio, and Amgen stock on Nasdaq reflects that combination of growth and late-stage trial news according to data available as of 24 July 2026. The California-based biopharmaceutical company has also expanded its market capitalization into the tens of billions of dollars, underlining its role as a large-cap constituent of major US equity indices.

Revenue growth and profitability metrics

According to Amgen’s most recent full-year financial report for 2024, the company generated total revenue of around $29 billion in 2024, compared with roughly $26 billion in 2023, an increase on the order of 10% over the prior year period. Within that total, product sales accounted for the clear majority of revenue, with the balance coming from collaboration, other revenue, and the contribution from acquired assets.

Amgen’s 2024 net income was reported in the multi-billion-dollar range as well, indicating that the company maintained a healthy profit margin on its biologics and oncology portfolio. Operating margin remained above one third of revenue in 2024, supported by a favorable mix of higher-margin biologic therapies and disciplined operating expense control in research, development, and selling, general, and administrative activities.

On an adjusted basis, Amgen reported earnings per share for 2024 clearly above $15, compared with a level in the mid-teens per share in 2023, implying mid- to high-single-digit EPS growth year on year. That progression reflects not only the higher revenue base but also cost synergies and financial discipline after the integration of recent acquisitions.

KRAS lung cancer data and pipeline developments

In the oncology pipeline, Amgen has reported updated clinical data for its KRAS G12C inhibitor in non-small cell lung cancer in 2024 and 2025, including overall response rates and progression-free survival in later-line settings that are broadly consistent with earlier readouts. Those data points are important because KRAS G12C mutations represent a meaningful molecular subset of lung cancer, and competitive dynamics in that target class influence both pricing and market share potential.

In addition to KRAS-targeted therapy, Amgen’s hematology and oncology franchise continues to be driven by products such as a bispecific antibody in multiple myeloma and an antibody-drug conjugate in solid tumors, each contributing hundreds of millions of dollars in annual revenue. For 2024, oncology and hematology product sales together accounted for a double-digit billion-dollar share of Amgen’s overall revenue mix, supporting the company’s positioning as a major oncology player.

Management has also highlighted the importance of early- and mid-stage assets across cardiology, inflammation, and rare disease, with multiple Phase II and Phase III programs underway as of 2026. The combination of incremental label expansions for existing biologics and potential first-in-class or best-in-class assets underpins Amgen’s medium-term growth narrative.

Guidance, cash flow, and shareholder returns

For 2025, Amgen has guided to revenue in the low- to mid-single-digit percentage growth range versus 2024, anchored by continued uptake in key growth drivers and partially offset by erosion in legacy products. The company’s outlook also calls for adjusted earnings per share growth broadly in line with revenue, as increased investment in research and development is balanced by ongoing efficiency measures.

Free cash flow remained robust in 2024, with Amgen generating more than $8 billion in operating cash flow and a substantial portion of that converting into free cash flow after capital expenditures. That level of cash generation supports both the company’s dividend and share repurchase program as well as bolt-on business development opportunities.

Amgen has maintained a recurring quarterly dividend, which on an annualized basis equated to more than $8 per share in 2024, up from a level in the mid-$7 range in 2023. The increase underscores a progressive dividend policy that has seen the payout rise consistently over recent years, while still leaving room for internal investment and debt reduction.

Market position and index role

Amgen is one of the larger constituents of the US biotechnology and pharmaceutical space by market capitalization, with a value well above $100 billion as of mid-2026. That scale secures Amgen’s presence in key US benchmarks such as the S&P 500 and specialized healthcare indices, reinforcing its relevance for institutional and passive investors.

Compared with some large-cap biotech peers, Amgen’s revenue base is more diversified across therapeutic areas, spanning oncology, inflammation, bone health, cardiovascular disease, and biosimilars. This diversification provides a degree of resilience against product-specific patent expiries and competitive challenges, although it also requires sustained investment to maintain leadership in several franchises simultaneously.

Debt levels, elevated after prior acquisitions, have been gradually managed down through a combination of earnings growth and disciplined capital allocation. Net debt to EBITDA has trended lower since the peak following recent large deals, giving Amgen more flexibility for future strategic moves.

Key product franchise snapshot

Amgen’s portfolio includes several flagship products across oncology, inflammation, and cardiovascular disease, each contributing materially to overall revenue. In 2024, multiple products individually generated annual sales in the low- to mid-single-digit billions of dollars, while a broad tail of smaller therapies and biosimilars added incremental contributions across regions.

Beyond established blockbusters, Amgen’s biosimilars business has gained traction in oncology and inflammation markets, leveraging the company’s biologics manufacturing expertise. Biosimilar revenue grew at a double-digit rate in 2024 from a base in the low single-digit billions of dollars, benefiting from expanded access and new launches in major markets.

Amgen stock and valuation context

Amgen stock trades on Nasdaq under the ticker AMGN and changes hands in US dollars, with a share price in mid-2026 that implies a price-to-earnings ratio in the mid-teens based on 2024 adjusted EPS. That valuation places Amgen broadly in line with, or at a modest premium to, several other large-cap US biopharmaceutical companies that combine mature cash-generative franchises with late-stage pipelines.

The shares also offer a dividend yield in the low- to mid-single-digit percentage range, based on the annualized dividend per share and the prevailing share price as of 24 July 2026. For some investors, that income component is an important part of the total-return profile alongside potential capital appreciation from earnings and pipeline progress.

Company overview and segments

Amgen organizes its business around a portfolio of innovative biologics and targeted small-molecule therapies, commercialized globally with a strong presence in the United States, Europe, and Asia-Pacific. The company’s research and development operations concentrate on areas with high unmet medical need, including oncology, immunology, bone health, and cardiovascular disease.

In 2024, the United States accounted for a significant majority of total revenue, with international markets contributing a sizeable minority share. Within international operations, Europe remains the largest region, while Japan and emerging markets show differentiated growth profiles depending on product lifecycles, reimbursement frameworks, and biosimilar competition.

Amgen also invests heavily in manufacturing infrastructure for biologic medicines, including large-scale facilities that can produce monoclonal antibodies and other complex modalities. This manufacturing footprint is an important competitive advantage because it supports both innovative products and biosimilar offerings, enabling the company to manage cost of goods and quality at scale.

Research spending and innovation pipeline

Research and development spending reached several billion dollars in 2024, representing a sizable percentage of total revenue. That R&D investment level underscores Amgen’s commitment to sustaining a diverse pipeline of early- and late-stage assets, with a particular emphasis on first-in-class and best-in-class candidates.

Across oncology, inflammation, and cardiometabolic disease, Amgen had dozens of clinical-stage programs ongoing as of 2026, including multiple Phase III studies that could support regulatory filings over the next few years. The success rate of late-stage programs will be a key determinant of Amgen’s ability to offset future patent expiries in mature brands.

Strategic collaborations with smaller biotechnology companies and academic institutions complement internal research activities, giving Amgen access to novel targets, platforms, and technologies. Such collaborations often involve upfront payments, milestones, and royalty structures that align incentives between partners.

Regulatory milestones and competitive landscape

Regulatory approvals and label expansions in major markets such as the United States, the European Union, and Japan are central to Amgen’s growth profile. In recent years, the company has secured new indications for several therapies across oncology and inflammation, supported by randomized Phase III trial data.

Competition in key markets remains intense, with innovative therapies from other large-cap pharmaceutical and biotech companies vying for market share alongside biosimilar entrants. For some of Amgen’s mature biologics, biosimilar competition has already led to price and volume pressure, which the company seeks to offset by growing newer products and expanding into additional indications.

The company’s ability to navigate health technology assessments, reimbursement negotiations, and pricing pressure across different regions will continue to influence revenue and margin dynamics. Value-based agreements and outcomes-focused contracts are among the tools used to align pricing with clinical benefit in some markets.

Capital structure and credit profile

Amgen’s balance sheet includes term debt issued in US dollars and other currencies, with maturities spread over multiple years to avoid refinancing concentration. The company’s investment-grade credit ratings reflect its strong cash flow generation and large scale, balanced against the inherent risks of the pharmaceutical industry and ongoing R&D requirements.

Management has used leverage to fund acquisitions and share repurchases in the past, but the stated intention has been to maintain a disciplined capital structure. Debt reduction, when combined with earnings growth, has helped bring leverage metrics back toward long-term targets following periods of elevated deal activity.

Cash and marketable securities on the balance sheet provide a buffer against near-term obligations and strategic flexibility for additional investment, whether in internal projects or external licensing and M&A opportunities.

ESG considerations and long-term themes

Environmental, social, and governance considerations are increasingly relevant for large-cap healthcare companies such as Amgen, influencing investor perceptions and index inclusion. The company reports on metrics such as access to medicines, diversity and inclusion, and environmental impact across its operations.

In the long term, demographic trends and rising healthcare needs point to sustained demand for treatments in oncology, cardiovascular disease, and chronic inflammatory conditions, all core areas for Amgen. At the same time, pricing scrutiny, policy changes, and scientific competition will shape how much value innovator companies can capture from that demand.

For long-horizon investors, the key questions center on Amgen’s ability to consistently translate its scientific capabilities and financial resources into differentiated therapies that meet regulator and payer expectations while sustaining attractive returns on invested capital.